Ginkgo Bioworks Holdings, Inc. · NYSE:DNA

Ginkgo Bioworks — Q3 2022 Earnings Presentation

35 slides from Ginkgo Bioworks's earnings presentation, Nov 14, 2022

1. Slide 1: Grow with Ginkgo: Q3 2022 Update & Business Review

   Grow with Ginkgo Q3 2022 Update & Business Review November 14, 2022

2. Slide 2: Disclaimer: Forward-Looking Statements

   Disclaimer Forward-Looking Statements This presentation, the conference call and webcast may contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, current expectations, operations and anticipated results of

3. Slide 3: Agenda

   Property of Ginkgo Bioworks — 3 Agenda Introduction Jason Kelly, Co-Founder and CEO Q3 2022 Financial Update Mark Dmytruk, CFO Q3 2022 UPDATE & BUSINESS REVIEW Strategic Review Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Anna Marie Wagner, SVP Corporate Development

4. Slide 4: Our mission: Make biology easier to engineer

   Our mission Make biology easier to engineer Q3 2022 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 4

5. Slide 5: Making biology easier to engineer by programming cells

   Property of Ginkgo Bioworks — 5 We aim to make biology easier to engineer for our customers by leveraging our platform for programming cells Q3 2022 UPDATE & BUSINESS REVIEW

6. Slide 6: Continuing to execute well in the third quarter of 2022

   Property of Ginkgo Bioworks — 6 Continuing to execute well in the third quarter of 2022 Progress on Key Metrics Active 85 Programs Government +15 New Programs in Q3 $289 million Year-to-date Biosecurity Revenue Pharma & Continued strength in Pharma & Biotech and Further traction in international exp

7. Slide 7: Society for Immunotherapy of Cancer (SITC) 2022

   Society for Immunotherapy of Cancer (SITC) 2022 Q3 2022 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 7

8. Slide 8: Agenda

   Property of Ginkgo Bioworks — 8 Agenda Introduction Jason Kelly, Co-Founder and CEO Q3 2022 Financial Update Mark Dmytruk, CFO Q3 2022 UPDATE & BUSINESS REVIEW Strategic Review Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Anna Marie Wagner, SVP Corporate Development

9. Slide 9: Total Ginkgo Revenue (Unaudited)

   Property of Ginkgo Bioworks — 9 Total Ginkgo Revenue (Unaudited) Biosecurity 129% Foundry Q3 2022 UPDATE & BUSINESS REVIEW -14% Note: Q3 2021 Foundry revenue included downstream value share revenue related to an equity milestone achievement by Cronos Group Inc.

10. Slide 10: Cell Programming Highlights (Unaudited)

    Property of Ginkgo Bioworks — 10 Cell Programming Highlights (Unaudited) New Programs Current Active Programs 57% 50% Q3 2022 UPDATE & BUSINESS REVIEW Total Active Customers Foundry Revenue ($M) 59% (29%) Q3 2021 Foundry revenue included a ~$13 million milestone payment

11. Slide 11: Biosecurity Highlights (Unaudited)

    Property of Ginkgo Bioworks — 11 Biosecurity Highlights (Unaudited) Concentric’s pathogen monitoring network has (*) Biosecurity Revenue ($M) delivered testing across most of the U.S. Demonstrated ability to deliver testing in diverse jurisdictions Q3 2022 UPDATE & BUSINESS REVIEW Biosecurity Gross

12. Slide 12: Q3 2022 Financial Summary (Unaudited)

    Property of Ginkgo Bioworks — 12 Q3 2022 Financial Summary (Unaudited) Three Months Ended Nine Months Ended In millions of USD September 30, September 30, except new programs and % YoY 2022 2021 % YoY 2022 2021 % YoY New programs launched 15 10 50% 39 21 86% Revenue: Foundry $ 25 $ 35 (29%) $ 90 $ 7

13. Slide 13: 2022 Full Year Outlook

    Property of Ginkgo Bioworks — 13 2022 Full Year Outlook In millions of USD Historical FY2022 Forecast except new programs and % YoY Second Original First Revision Third Revision FY2020 FY2021 (20-21) Revision (March 28) (May 16) (November 14) (August 15) New Programs 18 31 72% 60 60 60 55 - 60 Q3 20

14. Slide 14: Agenda

    Property of Ginkgo Bioworks — 14 Agenda Introduction Jason Kelly, Co-Founder and CEO Q3 2022 Financial Update Mark Dmytruk, CFO Q3 2022 UPDATE & BUSINESS REVIEW Strategic Review Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Anna Marie Wagner, SVP Corporate Development

15. Slide 15: We believe: Efficient Zymergen close

    Property of Ginkgo Bioworks — 15 We believe… 1 2 3 Efficient Zymergen close We’re excited about the Our Biosecurity business process provides strategic downstream value potential continues to evolve benefits from new program adds beyond K-12 COVID testing Q3 2022 UPDATE & BUSINESS REVIEW We were able t

16. Slide 16: We believe: Efficient Zymergen close

    Property of Ginkgo Bioworks — 16 We believe… 1 2 3 Efficient Zymergen close We’re excited about the Our Biosecurity business process provides strategic downstream value potential continues to evolve benefits from new program adds beyond K-12 COVID testing Q3 2022 UPDATE & BUSINESS REVIEW We were able t

17. Slide 17: Efficient closing timeline delivered more cash and upside opportunities

    Property of Ginkgo Bioworks — 17 Efficient closing timeline delivered more cash with the business and allows us to quickly pursue upside opportunities to drive further value Cash at Closing Upside Opportunities Product Portfolio Real Estate Zymergen delivered over $100 We are evaluating strategic alte

18. Slide 18: Team is an amazing fit to drive near-term Ginkgo goals

    Property of Ginkgo Bioworks — 18 Team is an amazing fit to drive near-term Ginkgo goals Automation & Software Product G&A Support ~55 employees ~65 employees ~65 employees Q3 2022 UPDATE & BUSINESS REVIEW Integrating the teams to advance Exploring strategic alternatives for Core team retained to ensu

19. Slide 19: We believe: downstream value from new programs

    Property of Ginkgo Bioworks — 19 We believe… 1 2 3 Efficient Zymergen close We’re excited about the Our Biosecurity business process provides strategic downstream value potential continues to evolve benefits from new program adds beyond K-12 COVID testing Q3 2022 UPDATE & BUSINESS REVIEW As we grow the

20. Slide 20: Several drivers of new program demand in 2023 and beyond

    Property of Ginkgo Bioworks — 20 Several drivers of new program demand in 2023 and beyond Growing Demand New Program Growth Execution Trend towards external innovation: Most Standardizing core offerings: leaning into our impactful trend for Ginkgo is the acceptance and strengths drives both efficiency

21. Slide 21: We expect near-term value to new programs

    Property of Ginkgo Bioworks — 21 We expect near-term value to new programs New programs expected to bring meaningful near-term benefits in connection with platform scaling and unit economics Builds Codebase Supports Foundry Scaling Generates R&D Fees Each new program generates learnings for Engineeri

22. Slide 22: We expect long-term value to new programs

    Property of Ginkgo Bioworks — 22 We expect long-term value to new programs New Program Additions Diverse Downstream Opportunities Downstream economics, regardless of structure, are negotiated to provide real Programs bring the potential to earn: upside far outweighing upfront fees, though we expect

23. Slide 23: We believe: Biosecurity business continues to evolve

    Property of Ginkgo Bioworks — 23 We believe… 1 2 3 Efficient Zymergen close We’re excited about the Our Biosecurity business process provides strategic downstream value potential continues to evolve benefits from new program adds beyond K-12 COVID testing Q3 2022 UPDATE & BUSINESS REVIEW We’ve develope

24. Slide 24: We are building the infrastructure for global biosecurity

    Property of Ginkgo Bioworks — 24 We are building the infrastructure for global biosecurity Collection Platform Analytics & Decision Support Core offering Recent module add-ons Disease Spread Pathogen Identification Detection of Genetic Modeling & Prediction and Characterization Engineering Developing

25. Slide 25: Biosecurity and biodefense as U.S. national security priorities

    Property of Ginkgo Bioworks — 25 Biosecurity and biodefense have been highlighted as national security priorities for the U.S. government and we stand ready to serve Executive Order on Advancing “We need to invest in and promote biosafety and biosecurity to ensure that Biotechnology and Biomanufactu

26. Slide 26: Infectious diseases do not respect borders; building global solutions

    Property of Ginkgo Bioworks — 26 Infectious diseases do not respect borders and we must build global solutions Africa CDC and Ginkgo Bioworks Ginkgo Bioworks and First Serv Announce Collaboration to Strengthen Announce Plans to Develop and Laboratory Network Capacity Across Implement Innovative Glob

27. Slide 27: Let's grow the world we want to see

    Let’s grow the world we want to see

28. Slide 28: Agenda

    Property of Ginkgo Bioworks — 28 Agenda Introduction Jason Kelly, Co-Founder and CEO Q3 2022 Financial Update Mark Dmytruk, CFO Q3 2022 UPDATE & BUSINESS REVIEW Strategic Review Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Anna Marie Wagner, SVP Corporate Development

29. Slide 29: Appendix

    APPENDIX

30. Slide 30: Cell Program Counts

    Property of Ginkgo Bioworks — 30 Cell Program Counts Three Months Ended September 30, Nine Months Ended September 30, LTM (1) 2022 2021 2022 2021 2022 New Programs 15 10 39 21 49 Current Active Programs 85 54 92 61 99 Cumulative Programs 144 95 144 95 144 Q3 2022 UPDATE & BUSINESS REVIEW (1) Last tw

31. Slide 31: Adjusted EBITDA Reconciliation (Unaudited)

    Property of Ginkgo Bioworks — 31 Adjusted EBITDA Reconciliation (Unaudited) Three Months Ended Nine Months Ended In millions of USD September 30, September 30, 2022 2021 2022 2021 Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders $ (669.1) $ (101.9) $ (1,928.4) $ (229.4) Interest

32. Slide 32: Stock-Based Compensation (Unaudited)

    Property of Ginkgo Bioworks — 32 Stock-Based Compensation (Unaudited) In millions of USD Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 % YoY 2022 2021 % YoY Total Stock-Based Compensation $ 563.4 $ 0.1 NM $ 1,829.7 $ 14.8 NM Amount included in Research and Development ex

33. Slide 33: Foundry Revenue (Unaudited)

    Property of Ginkgo Bioworks — 33 Foundry Revenue (Unaudited) In millions of USD, except percentages Three Months Ended September 30, Nine Months Ended September 30, 2022 % of Total 2021 % of Total 2022 % of Total 2021 % of Total Related Parties $ 10.0 41% $ 13.1 38% $ 31.6 35% $ 36.7 47% Third Parti

34. Slide 34: Segment Information (Unaudited)

    Property of Ginkgo Bioworks — 34 Segment Information (Unaudited) Three Months Ended Nine Months Ended In millions of USD September 30, September 30, 2022 2021 % YoY 2022 2021 % YoY Revenue: Foundry $ 25 $ 35 (29%) $ 90 $ 79 15% Biosecurity 42 43 (3%) 289 87 234% Total Revenue 66 78 (14%) 379 165 129

35. Slide 35: Share Supplement

    Property of Ginkgo Bioworks — 35 Share Supplement Illustrative Fully-Diluted Share Count - Includes Zymergen Close Shares in millions Basic Shares(1) 1,779.8 RSUs(2) 181.3 Options (Treasury-stock method)(3) 16.1 Q3 2022 UPDATE & BUSINESS REVIEW Fully-Diluted Shares 1,977.2 Memo: Remaining Earnout Sh

Ginkgo Bioworks Holdings — Q3 2022 Earnings Presentation on 6ix